# Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies

> **NCT07014254** · NA · NOT_YET_RECRUITING · sponsor: **Xijing Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (PDAC)
- Adenocarcinoma of the Stomach
- Colorectal Cancer Metastatic
- Neuroendocrine Tumor (NET)

## Interventions

- **DRUG:** 177Lu-CTR-FAPI nuclide-targeted therapy

## Key facts

- **NCT ID:** NCT07014254
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014254, "Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07014254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*